Early Access Program for Pritelivir

Early access programs—also known as expanded access or compassionate use programs—are sometimes offered by pharmaceutical companies when a drug is in the later stages of clinical trials, particularly if the drug has the potential to treat a serious or life-threatening condition and there are no adequate treatment options available.

Aicuris is currently leading a Phase 3 clinical trial for Pritelivir which is currently recruiting!

Led by Herpes Cure Advocacy, and frustrated with the lack of options, many in the patient community have been advocating for better therapies. One option for certain patients who meet criteria may be Priteliver, developed by AiCuris, which is currently in stage 3 clinical trials.

Pritelivir is available through an Expanded Access Program (EAP) for patients with treatment-resistant herpes simplex virus (HSV) infections. The EAP allows patients to access Pritelivir who are unable to participate in clinical trials or who have exhausted other treatment options. 

Eligibility for Early Access to Pritelivir

• Patients must be immunocompromised and have acyclovir-resistant HSV infections 
• Patients must be unable to use other FDA-approved treatments 
• Patients must have exhausted all other treatment options 
• Patients must be willing to use contraception and take a pregnancy test if they are of childbearing age 
• Patients must be willing to sign an informed consent form 

How to access? 

• A patient’s treating physician must request and approve the treatment
• The patient’s treating physician will oversee the treatment
• To access Pritelivir, patients will need to share the request form to myTomorrows with your prescribing physician

Who is involved?

• AiCuris: Company developing Pritelivir
• myTomorrows: A company that works with AiCuris to facilitate access to pritelivir for patients.

---

Follow us!

• Twitter
• Facebook
• Reddit
• Mail
• Instagram
• Link
• TikTok
• LinkedIn